Pieris Pharmaceuticals to Host First Quarter 2018 Investor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
31
Pieris Pharmaceuticals to Host First Quarter 2018 Investor Call and Corporate Update on May 10, 2018

BOSTON, MA --(Marketwired - May 01, 2018) - Pieris Pharmaceuticals, Inc. ( NASDAQ : PIRS ) , a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, announced today that it will host a first quarter 2018 investor call on Thursday, May 10, 2018 at 8:00 AM (EDT) to discuss financial results and provide a corporate update.

To access the call, participants may dial 877-407-8920 (US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call.

An archived replay of the call will be available for 30 days by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472.

About Pieris Pharmaceuticals Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com .

Forward Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at  www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and the Company's Quarterly Reports on Form 10-Q.

Company Contact: Allan Reine SVP & Chief Financial Officer +1-857-444-4276 reine@pieris.com Investor Relations Contact: Maria Kelman Director, Investor Relations +1-857-362-9635 kelman@pieris.com Media Inquiries: Trophic Communications Gretchen Schweitzer +49-89-238-87730 schweitzer@trophic.eu

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Insiders Buy Up on MicroStrategy While Analysts Expect Growth

Updated Category News Views 198

Insider Purchases Indicate Confidence in MicroStrategy Recently, insiders at MicroStrategy Incorporated (NASDAQ: MSTR) have made notable stock purchases that are turning heads in the financial community. Even though there were increases in insider share sales in the last quarter, which reached a two-year peak, the market has not reacted unfavorably. Most of these sales...

Continue Reading
Burlington Stores Insider Transaction: Stephen Ferroni's Move

Updated Category News Views 174

Burlington Stores Insider Transaction Details In a significant move recently disclosed in an SEC filing, Stephen Ferroni, the Senior Vice President at Burlington Stores, made headlines by exercising company stock options. This transaction, involving the exercise of options for 1,123 shares, amounted to a transaction value of approximately $200,331. The filing highlights...

Continue Reading
Clairvest Group's Strategic Acquisition of MGM Northfield Park

Updated Category News Views 371

Clairvest Group Expands Horizons with MGM Northfield Park Acquisition Exciting developments are shaping the landscape for Clairvest Group Inc. as they embark on a significant acquisition journey with MGM Northfield Park. This strategic move not only highlights Clairvest's commitment to growth in the gaming sector but also enhances their longstanding reputation for...

Continue Reading
Innovent Biologics Showcases Promising Research at ADA 85th Sessions

Updated Category News Views 576

Innovent Biologics Presents Cutting-Edge Research at ADA Innovent Biologics, Inc. (HKEX: 01801) has made significant advancements in the biopharmaceutical industry, focusing on innovative treatments for oncology, autoimmune diseases, and metabolic conditions. Recently, the company announced that it will showcase exciting results from its research pipeline at the American...

Continue Reading
Promising Results from HERIZON-GEA-01 Trial Support Ziihera®

Updated Category News Views 288

Encouraging HERIZON-GEA-01 Phase 3 Findings Reinforce Ziihera®’s Role Ziihera, when combined with chemotherapy, has demonstrated a significant improvement in progression-free survival (PFS) compared to trastuzumab and chemotherapy combinations. It also showed a strong trend towards enhancing overall survival (OS) at the first analysis. Clinical Outcomes of Ziihera in...

Continue Reading